Skip to main content

Advertisement

Fig. 5 | Molecular Cancer

Fig. 5

From: PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models

Fig. 5

Impact of single vs. dual MET/PI3K inhibition on downstream signaling and cell proliferation in non-MET-driven HNC models. a, cells were serum-starved for 24 h, treated with tepotinib for 2 h, and then stimulated with the MET ligand SF/HGF for 10 min. b, cells were treated for 16 h with half-EC50 concentrations of tepotinib and pictilisib, alone and in combination, and then lysed. c, cells were treated for 72 h with single or dual MET/PI3K inhibitors at various concentrations. Cell proliferation was assessed using a resazurin-reduction based assay and combinatorial effects were determined using the excess over bliss, with values above 0 indicating more-than-additive effects (bold-italic numbers indicate values significantly different to 0 according to one-sample t-test)

Back to article page